Delayed
Deutsche Boerse AG
08:57:50 17/07/2024 BST
|
5-day change
|
1st Jan Change
|
0.22
EUR
|
-3.51%
|
|
-11.65%
|
+0.55%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
301.2
|
201.5
|
624.1
|
551.7
|
159.1
|
321.9
|
-
|
-
|
Enterprise Value (EV)
1 |
210.5
|
131.5
|
402.9
|
434.3
|
-10.48
|
146.7
|
54.92
|
256.9
|
P/E ratio
|
-2.44
x
|
-4.74
x
|
-9.33
x
|
-6.23
x
|
-1.93
x
|
-3.59
x
|
-2.26
x
|
-1.96
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
41.8
x
|
5.11
x
|
17.5
x
|
89
x
|
17.7
x
|
10.8
x
|
6.18
x
|
31.6
x
|
EV / Revenue
|
29.2
x
|
3.34
x
|
11.3
x
|
70
x
|
-1.16
x
|
4.94
x
|
1.06
x
|
25.2
x
|
EV / EBITDA
|
-1.77
x
|
-3.42
x
|
-6.77
x
|
-5.12
x
|
0.12
x
|
-2.4
x
|
-1.84
x
|
-1.99
x
|
EV / FCF
|
-1.41
x
|
-2.07
x
|
-8.27
x
|
-4.25
x
|
0.17
x
|
-6.11
x
|
-0.32
x
|
-1.26
x
|
FCF Yield
|
-71.1%
|
-48.3%
|
-12.1%
|
-23.5%
|
572%
|
-16.4%
|
-310%
|
-79.4%
|
Price to Book
|
1.63
x
|
1.42
x
|
2.22
x
|
2.86
x
|
0.79
x
|
0.97
x
|
0.98
x
|
2.59
x
|
Nbr of stocks (in thousands)
|
24,288
|
24,276
|
55,724
|
55,724
|
55,830
|
112,168
|
-
|
-
|
Reference price
2 |
12.40
|
8.300
|
11.20
|
9.900
|
2.850
|
2.870
|
2.870
|
2.870
|
Announcement Date
|
13/02/20
|
26/02/21
|
15/02/22
|
15/02/23
|
15/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
7.2
|
39.4
|
35.7
|
6.2
|
9
|
29.72
|
52.05
|
10.2
|
EBITDA
1 |
-118.9
|
-38.5
|
-59.5
|
-84.8
|
-88.7
|
-61.2
|
-29.8
|
-129
|
EBIT
1 |
-126
|
-42.9
|
-62.1
|
-87.4
|
-91.4
|
-97.32
|
-96.41
|
-167.3
|
Operating Margin
|
-1,750%
|
-108.88%
|
-173.95%
|
-1,409.68%
|
-1,015.56%
|
-327.4%
|
-185.24%
|
-1,639.87%
|
Earnings before Tax (EBT)
1 |
-123.3
|
-42.6
|
-62.6
|
-88.8
|
-89.3
|
-94.09
|
-95.84
|
-166.9
|
Net income
1 |
-123.4
|
-42.6
|
-63.1
|
-88.8
|
-89.3
|
-94.09
|
-95.84
|
-166.9
|
Net margin
|
-1,713.89%
|
-108.12%
|
-176.75%
|
-1,432.26%
|
-992.22%
|
-316.52%
|
-184.13%
|
-1,636.68%
|
EPS
2 |
-5.080
|
-1.750
|
-1.200
|
-1.590
|
-1.480
|
-0.7990
|
-1.271
|
-1.461
|
Free Cash Flow
1 |
-149.7
|
-63.5
|
-48.7
|
-102.2
|
-60
|
-24
|
-170
|
-204
|
FCF margin
|
-2,079.04%
|
-161.17%
|
-136.41%
|
-1,648.39%
|
-666.67%
|
-80.74%
|
-326.61%
|
-2,000%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
13/02/20
|
26/02/21
|
15/02/22
|
15/02/23
|
15/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2021 S1
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
11.4
|
18.8
|
15.3
|
0.9
|
0.9
|
1.8
|
2
|
2.5
|
0.8
|
2.6
|
3.3
|
1
|
4.7
|
0.6
|
0.45
|
1.5
|
0.55
|
0.6
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-
|
-
|
-
|
-22.1
|
-
|
-14.6
|
-18.7
|
-
|
-
|
-
|
-24.1
|
-20.8
|
-27.4
|
-33.38
|
-36.8
|
-35.34
|
-36.36
|
Operating Margin
|
-
|
-
|
-
|
-
|
-2,455.56%
|
-
|
-730%
|
-748%
|
-
|
-
|
-
|
-2,410%
|
-442.55%
|
-4,566.67%
|
-7,416.86%
|
-2,453.33%
|
-6,425.78%
|
-6,060.35%
|
Earnings before Tax (EBT)
1 |
-36.1
|
-25.4
|
-24.3
|
-32.7
|
-23.1
|
-55.9
|
-14.8
|
-18.1
|
-18.9
|
-26.6
|
-45.5
|
-23.6
|
-20.3
|
-26.1
|
-32.83
|
-34.4
|
-34.79
|
-35.81
|
Net income
1 |
-36.1
|
-25.5
|
-24.3
|
-32.7
|
-23.1
|
-55.9
|
-14.8
|
-18.1
|
-18.9
|
-26.6
|
-45.5
|
-23.6
|
-20.3
|
-26.1
|
-32.83
|
-34.4
|
-34.79
|
-35.81
|
Net margin
|
-316.67%
|
-135.64%
|
-158.82%
|
-3,633.33%
|
-2,566.67%
|
-3,105.56%
|
-740%
|
-724%
|
-2,362.5%
|
-1,023.08%
|
-1,378.79%
|
-2,360%
|
-431.91%
|
-4,350%
|
-7,294.64%
|
-2,293.33%
|
-6,325.78%
|
-5,968.68%
|
EPS
2 |
-1.490
|
-0.5700
|
-0.4400
|
-0.5900
|
-0.4200
|
-1.000
|
-0.2700
|
-0.3200
|
-0.3400
|
-0.4700
|
-0.8100
|
-0.4200
|
-0.2800
|
-0.2300
|
-0.2645
|
-0.3000
|
-0.3175
|
-0.3225
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20/08/20
|
19/08/21
|
15/02/22
|
28/04/22
|
19/08/22
|
19/08/22
|
03/11/22
|
15/02/23
|
27/04/23
|
18/08/23
|
18/08/23
|
27/10/23
|
15/02/24
|
30/04/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
90.6
|
70
|
221
|
117
|
170
|
175
|
267
|
65
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-150
|
-63.5
|
-48.7
|
-102
|
-60
|
-24
|
-170
|
-204
|
ROE (net income / shareholders' equity)
|
-50.2%
|
-26.1%
|
-29.8%
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
7.590
|
5.840
|
5.040
|
3.460
|
3.610
|
2.950
|
2.930
|
1.110
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
1.44
|
5.4
|
-
|
0.4
|
0.3
|
-
|
1
|
3
|
Capex / Sales
|
19.94%
|
13.71%
|
-
|
6.45%
|
3.33%
|
-
|
1.92%
|
29.41%
|
Announcement Date
|
13/02/20
|
26/02/21
|
15/02/22
|
15/02/23
|
15/02/24
|
-
|
-
|
-
|
Last Close Price
2.87
SEK Average target price
20.91
SEK Spread / Average Target +628.44% Consensus |
1st Jan change
|
Capi.
|
---|
| +20.17% | 126B | | +24.67% | 118B | | +22.97% | 27.87B | | -17.74% | 20.95B | | -16.31% | 16.92B | | -15.21% | 16.18B | | +11.91% | 14.84B | | -47.10% | 14.79B | | +54.50% | 14.08B |
Bio Therapeutic Drugs
|